P144 (TGF-β inhibitor peptide)

About DISITBiotech

DISIT Biotech, founded in 2019 and based in Barcelona, is a preclinical-stage biotech developing peptide-based inhibitors of TGF-β to treat complications from cancer radiotherapy, such as fibrosis. The company has garnered recognition through awards and grants, indicating validation of its innovative approach. It operates as a private, pre-revenue entity, advancing its lead asset through research and preclinical development with a focus on translating scientific discovery into clinical solutions for global health.

Therapeutic Areas